Status:
COMPLETED
A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects
Lead Sponsor:
Biogen
Conditions:
Healthy
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
Rationale for the Study: The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of Avonex in Chinese healthy volunteer subjects. Data from this study w...
Detailed Description
Rationale for the Study: The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of Avonex in Chinese healthy volunteer subjects. Data from this study w...
Eligibility Criteria
Inclusion
- Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
- Subjects of Chinese origin (at least both maternal and paternal grandparents of Chinese origin).
- Body mass index (BMI) within the range of 18.5 to 30 kg/m2 (inclusive).
- All male subjects and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.
Exclusion
- History of seizure disorder or unexplained blackouts OR history of a seizure within 6 months prior to Day 1.
- History of suicidal ideation or an episode of clinically severe depression (as determined by the Investigator) within 6 months prior to Day 1.
- Any clinically significant presence (as determined by the Investigator) of cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease.
- Positive test result for hepatitis C antibody (HCV Ab), or current hepatitis B infection at Screening.
- Known history of human immunodeficiency virus (HIV).
- Clinically significant abnormal laboratory values.
- History of alcohol abuse (as defined by the Investigator), or a positive blood screen test for presence for alcohol at Screening.
- History of drug abuse (as defined by the Investigator), or a positive urinary screen test for presence of cocaine and morphine.
- Premalignant and malignant disease.
- History of clinically significant severe allergic or anaphylactic reactions.
- Known allergy to any component of the Avonex formulation.
- History of hypersensitivity or intolerance to prophylactic analgesic medication that would preclude use during the study.
- Clinically significant abnormal electrocardiogram (ECG) values as determined by the Investigator.
- Known allergy to interferon beta-1a.
- Active bacterial or viral infection.
- Female subjects who are pregnant or currently breastfeeding.
- Previous participation in another investigational drug study within the last 1 month or 7 half-lives, whichever is longer, or previous participation in this study.
- Treatment with any prescription medication within 14 days of Day 1.
- Treatment with any over-the-counter products within the 14 days prior to Day 1.
- Donation of blood (500 mL or greater) within 56 days prior to Day 1.
- Inability to comply with study requirements
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01416207
Start Date
August 1 2011
End Date
October 1 2011
Last Update
November 4 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Shanghai, China